C4X Stock Overview
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Valerio Therapeutics Société anonyme Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.11 |
52 Week High | €0.33 |
52 Week Low | €0.084 |
Beta | 1.63 |
1 Month Change | 0% |
3 Month Change | -13.71% |
1 Year Change | -61.79% |
3 Year Change | -84.10% |
5 Year Change | -86.98% |
Change since IPO | -99.20% |
Recent News & Updates
Recent updates
Shareholder Returns
C4X | DE Biotechs | DE Market | |
---|---|---|---|
7D | -6.1% | 1.6% | -1.4% |
1Y | -61.8% | -21.6% | 2.2% |
Return vs Industry: C4X underperformed the German Biotechs industry which returned -21.6% over the past year.
Return vs Market: C4X underperformed the German Market which returned 2.2% over the past year.
Price Volatility
C4X volatility | |
---|---|
C4X Average Weekly Movement | 14.0% |
Biotechs Industry Average Movement | 5.0% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: C4X's share price has been volatile over the past 3 months.
Volatility Over Time: C4X's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 39 | Shefali Agarwal | valeriotx.com |
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform.
Valerio Therapeutics Société anonyme Fundamentals Summary
C4X fundamental statistics | |
---|---|
Market cap | €16.64m |
Earnings (TTM) | -€19.73m |
Revenue (TTM) | €1.44m |
11.5x
P/S Ratio-0.8x
P/E RatioIs C4X overvalued?
See Fair Value and valuation analysisEarnings & Revenue
C4X income statement (TTM) | |
---|---|
Revenue | €1.44m |
Cost of Revenue | €491.00k |
Gross Profit | €952.00k |
Other Expenses | €20.69m |
Earnings | -€19.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.13 |
Gross Margin | 65.97% |
Net Profit Margin | -1,367.64% |
Debt/Equity Ratio | 55.3% |
How did C4X perform over the long term?
See historical performance and comparison